Table 3:
Multivariate Outcomes in Myeloablative Related and Unrelated Donor Transplant
| Tac+MTX | CSA+MMF | CSA+MTX | Tac+MMF | |
|---|---|---|---|---|
| Matched Related donor (MRD) HR (95% CI), P-value | ||||
| aGVHD grade 2–4 | Ref (1.00) | 1.65 (1.24–2.20) P<0.001 | 1.17 (1.04–1.33) P=0.010 | 1.05 (0.83–1.34) P=0.661 |
| aGVHD grade 3–4 | 1.92 (1.31–2.83) P<0.001 | 1.13 (0.92–1.37) P=0.283 | 1.19 (0.85–1.66) P=0.319 | |
| cGVHD* <5 months | 1.34 (0.83–2.17) P=0.233 | 1.41 (1.20–1.67) P<0.001 | 1.28 (0.94-.74) P=0.119 | |
| cGVHD* ≥5 months | 0.56 (0.34–0.95) P=0.030 | 0.74 (0.65–0.85) P<0.001 | 0.92 (0.71–1.19) P=0.512 | |
| TRM* <5 months | 4.03 (2.61–6.23) P<0.001 | 2.29 (1.78–2.95) P<0.001 | 1.17 (0.71–1.94) P=0.537 | |
| TRM* ≥5 months | 1.38 (0.78–2.44) P=0.275 | 0.83 (0.67–1.03) P=0.095 | 0.90 (0.59–1.36) P=0.609 | |
| Relapse | 1.43 (1.05–1.93) P=0.022 | 0.86 (0.74–0.98) P=0.029 | 0.92 (0.73–1.14) P=0.444 | |
| OS* <5 months | 2.31 (1.73–3.09) P<0.001 | 1.27 (1.10–1.48) P=0.002 | 1.05 (0.81–1.37) P=0.704 | |
| OS* ≥5 months | 0.94 (0.62–1.43) P=0.767 | 0.74 (0.64–0.87) P<0.001 | 0.92 (0.70–1.20) P=0.530 | |
| Unrelated donor (URD) HR (95% CI), P-value | ||||
| aGVHD, grade 2–4 | Ref (1.00) | 1.49 (1.08–2.07) P=0.016 | 1.00 (0.90–1.12) P=0.961 | 1.14 (0.99–1.32) P=0.066 |
| aGVHD, grade 3–4 | 2.31 (1.57–3.42) P<0.001 | 1.02 (0.87–1.20) P=0.806 | 1.26 (1.02–1.56) P=0.030 | |
| cGVHD* <4 months | 1.54 (0.79–2.98) P=0.203 | 1.62 (1.35–1.93) P<0.001 | 1.34 (1.04–1.73) P=0.022 | |
| cGVHD* ≥4 months | 0.92 (0.52–1.63) P=0.779 | 0.85 (0.74–0.98) P=0.025 | 1.47 (1.24–1.75) P<0.001 | |
| TRM* <4 months | 3.09 (2.00–4.77) P<0.001 | 1.24 (1.02–1.51) P=0.030 | 1.02 (0.77–1.36) P=0.896 | |
| TRM* ≥4 months | 0.89 (0.42–1.90) P=0.763 | 1.00 (0.84–1.20) P=0.979 | 1.45 (1.16–1.81) P=0.001 | |
| Relapse | 0.81 (0.50–1.32) P=0.398 | 0.97 (0.85–1.12) P=0.699 | 0.93 (0.78–1.12) P=0.449 | |
| OS* <4 months | 2.36 (1.67–3.35) P<0.001 | 1.23 (1.08–1.41) P=0.002 | 1.20 (1.01–1.44) P=0.044 | |
| OS* ≥4 months | 1.10 (0.64–1.89) P=0.730 | 0.91 (0.79–1.05) P=0.221 | 1.34 (1.12–1.61) P=0.001 | |
*
Given differential effects over time (non-proportional hazards), models were constructed breaking the post-transplant time course into 2 periods, using the maximized partial likelihood method to find the most appropriate breakpoint.